FDA Bestows Breakthrough Status to GSK’s Jemperli for Advanced Rectal Cancer with dMMR/MSI-H Markers
GSK plc has disclosed that the United States Food and Drug Administration (FDA) has awarded Breakthrough Therapy Designation to Jemperli (dostarlimab) for patients dealing with locally advanced mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) rectal cancer. The Breakthrough Therapy […]